People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.
Objective:
To report COVID-19 rates in pwMS according to vaccine serology.
Methods:
PwMS with available (1) serology 2–12 weeks following COVID-19 vaccine 2 and/or vaccine 3 and (2) clinical data on COVID-19 infection/hospitalisation were included. Logistic regression was performed to examine whether seroconversion following vaccination predicted risk of subsequent COVID-19 infection after adjusting for potential confounders. Rates of severe COVID-19 (requiring hospitalisation) were also calculated.
Results:
A total of 647 pwMS were included (mean age 48 years, 500 (77%) female, median Expanded Disability Status Scale (EDSS) 3.5% and 524 (81%) exposed to DMT at the time of vaccine 1). Overall, 472 out of 588 (73%) were seropositive after vaccines 1 and 2 and 222 out of 305 (73%) after vaccine 3. Seronegative status after vaccine 2 was associated with significantly higher odds of subsequent COVID-19 infection (odds ratio (OR): 2.35, 95% confidence interval (CI): 1.34–4.12, p = 0.0029), whereas seronegative status after vaccine 3 was not (OR: 1.05, 95% CI: 0.57–1.91). Five people (0.8%) experienced severe COVID-19, all of whom were seronegative after most recent vaccination.
Conclusion:
Attenuated humoral response to initial COVID-19 vaccination predicts increased risk of COVID-19 in pwMS, but overall low rates of severe COVID-19 were seen.
TallantyreECVickaryousNAndersonV, et al. COVID-19 vaccine response in people with multiple sclerosis. Ann Neurol2022; 91(1): 89–100.
2.
AchironAMandelMDreyer-AlsterS, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord2021; 14. DOI: 10.1177/17562864211012835.
3.
SchiavettiICordioliCStromilloML, et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler2022; 28(13): 2106–2111.
4.
SormaniMPSchiavettiILandiD, et al. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler2022; 28(7): 1034–1040.
5.
SormaniMPDe RossiNSchiavettiI, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol2021; 89(4): 780–789.
6.
LouapreCCollonguesNStankoffB, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol2020; 77(9): 1079–1088.
7.
AgrawalUKatikireddiSVMcCowanC, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): A prospective cohort study. Lancet Respir Med2021; 9(12): 1439–1449.
8.
GhadiriFSahraianMAAzimiA, et al. The study of COVID-19 infection following vaccination in patients with multiple sclerosis. Mult Scler Relat Disord2022; 57: 103363.
9.
PanditLSudhirAMalliC, et al. COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry. Mult Scler Relat Disord2022; 66: 104033.
10.
GarjaniAPatelSBharkhadaD, et al. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord2022; 57: 103458.
11.
DisantoGGalanteACantu’M, et al. Longitudinal postvaccine SARS-CoV-2 immunoglobulin G titers, memory B-cell responses, and risk of COVID-19 in multiple sclerosis over 1 year. Neurol Neuroimmunol Neuroinflamm2023; 10(1): e200043.
12.
SormaniMPSchiavettiIIngleseM, et al. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine2022; 80: 104042.
13.
BstehGGradlCHeschlB, et al. Impact of vaccination on COVID-19 outcome in multiple sclerosis. Eur J Neurol. Epub ahead of print 5 July 2022. DOI: 10.1111/ene.15488.
14.
Van KempenZLEStalmanEWSteenhuisM, et al. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry2023; 94(4): 280–283.
15.
RäuberSWillisonAKorsenM, et al. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab. Front Immunol2022; 13: 1037214.
16.
SmithTEMadhavanMGratchD, et al. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. Mult Scler Relat Disord2022; 60: 103735.
17.
SmithJBGonzalesEGLiBH, et al. Analysis of rituximab use, time between rituximab and SARS-CoV-2 vaccination, and COVID-19 hospitalization or death in patients with multiple sclerosis. JAMA Netw Open2022; 5(12): e2248664.
18.
JakimovskiDZakalikKAwanS, et al. COVID-19 vaccination in multiple sclerosis and inflammatory diseases: Effects from disease-modifying therapy, long-term seroprevalence and breakthrough infections. Vaccines2022; 10(5): 695.
19.
TallantyreECScurrMJVickaryousN, et al. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Mult Scler Relat Disord2022; 64: 103937.
20.
LevinEGLustigYCohenC, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med2021; 385(24): e84.
21.
ZavaTTZavaDT. Validation of dried blood spot sample modifications to two commercially available COVID-19 IgG antibody immunoassays. Bioanalysis2021; 13(1): 13–28.
22.
TuohyOCostelloeLHill-CawthorneG, et al. Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J Neurol Neurosurg Psychiatry2015; 86(2): 208–215.
23.
De StefanoNSormaniMPGiovannoniG, et al. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Mult Scler2022; 28(1): 111–120.
24.
BakerDPryceGJamesLK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord2020; 44: 102279.
25.
Zhovtis RyersonLLiXGoldbergJD, et al. Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm2020; 7(2): e672.
26.
IannettaMLandiDColaG, et al. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. Mult Scler Relat Disord2021; 55: 103157.
27.
Alfonso-DunnRLinJKirschnerV, et al. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Front Immunol2022; 13: 926318.
28.
KisterICurtinRPeiJ, et al. Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies. Ann Clin Transl Neurol2022; 9(10): 1643–1659.
29.
GuerreraGMandelliAFinardiA, et al. Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Mult Scler2022; 28(12): 1937–1943.
30.
SchwarzTOttoCJonesTC, et al. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Mult Scler2022; 28(7): 1041–1050.
31.
KisterIPatskovskyYCurtinR, et al. Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: A multi-ethnic observational study. Ann Neurol2022; 91(6): 782–795.
32.
MadelonNHeikkilaNSabater RoyoI, et al. Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol2022; 79(4): 399–404.
33.
SabatinoJJJrMittlKRowlesWM, et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight2022; 7(4): e156978.
34.
MadelonNLauperKBrevilleG, et al. Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: A prospective cohort study. Clin Infect Dis2022; 75(1): e1037–e1045.
35.
TortorellaCAielloAGasperiniC, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology2022; 98(5): e541–e554.
36.
IannettaMLandiDColaG, et al. B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: Immunological patterns and clinical implications. Front Immunol2021; 12: 796482.
37.
KatzJDBouleyAJJungquistRM, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord2022; 57: 103382.
38.
Meyer-ArndtLBraunJFauchereF, et al. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. J Neurol Neurosurg Psychiatry2022; 93(9): 960–971.
39.
RolfesLPawlitzkiMPfeufferS, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm2021; 8(5): e1035.
40.
PlotkinSA. Correlates of protection induced by vaccination. Clin Vaccine Immunol2010; 17: 1055–1065.
